Viral persistence and chronicity in hepatitis C virus infection: Role of T-cell apoptosis, senescence and exhaustion

Cells

Volumn 7, Issue 10, 2018, Pages

  Barathan, Muttiah ^a   Mohamed, Rosmawati ^a   Yong, Yean K ^b   Kannan, Meganathan ^c   Vadivelu, Jamuna ^a   Saeidi, Alireza ^a   Larsson, Marie ^d   Shankar, Esaki Muthu ^c  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b Xiamen University   (Malaysia)

^c CENTRAL UNIVERSITY OF TAMIL NADU   (India)

^d LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Apoptosis; Chronic infection; Hepatitis C virus; Immunity; Viral persistence

Indexed keywords

ADP RIBOSYL CYCLASE/CYCLIC ADP RIBOSE HYDROLASE 1; B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; CASPASE 8; CD161 ANTIGEN; CD27 ANTIGEN; CD28 ANTIGEN; CD57 ANTIGEN; CYTOCHROME C; CYTOKINE; FAS LIGAND; GRANZYME; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; HLA DR ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 7 RECEPTOR; NONSTRUCTURAL PROTEIN 4B; NONSTRUCTURAL PROTEIN 5B; PERFORIN; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN BCL 2; PROTEIN BID; PROTEIN MCL 1; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR SUPPRESSOR PROTEIN; UNINDEXED DRUG;

ACUTE HEPATITIS C; ANTIGEN PRESENTING CELL; APOPTOSIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL AGING; CELL CYCLE CHECKPOINT; CELL DIFFERENTIATION; CELL PROLIFERATION; CHRONIC HEPATITIS C; CHRONICITY; DENDRITIC CELL; ENZYME ACTIVATION; EXHAUSTION; GENE MUTATION; GENOTYPE; HEPATITIS C; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOSENESCENCE; MUCOSAL-ASSOCIATED INVARIANT T CELL; PATHOGENESIS; PERSISTENT VIRUS INFECTION; PHENOTYPE; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; UPREGULATION;

EID: 85059109284     PISSN: None     EISSN: 20734409     Source Type: Journal    
DOI: 10.3390/cells7100165     Document Type: Review

References (81)

1. Pfaender, S.; Brown, R.J.; Pietschmann, T.; Steinmann, E. Natural reservoirs for homologs of hepatitis C virus. Emerg. Microbes Infect. 2014, 3, e21.
2. Li, H.C.; Lo, S.Y. Hepatitis C virus: Virology, diagnosis and treatment. World J. Hepatol. 2015, 7, 1377-1389.
3. Pinter, M.; Trauner, M.; Peck-Radosavljevic, M.; Sieghart, W. Cancer and liver cirrhosis: Implications on prognosis and management. ESMO Open 2016, 1, e000042.
4. Khan, A.A.; Ahmad, H.; Saif, N.; Idrees, M.; Bajwa, M.A. Frequency distribution of hepatitis in three districts of Hazara division. Asian J. Med. Sci. 2010, 2, 37-39.
5. Palumbo, E. Pegylated interferon and ribavirin treatment for hepatitis C virus infection. Ther. Adv. Chronic Dis. 2011, 2, 39-45.
6. Ghany, M.G.; Strader, D.B.; Thomas, D.L.; Seeff, L.B. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology 2009, 49, 1335-1374.
7. Scheel, T.K.H.; Rice, C.M. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat. Med. 2013, 19, 837-849.
8. Park, S.H.; Rehermann, B. Immune responses to HCV and other hepatitis viruses. Immunity 2014, 40, 13-24.
9. Messina, J.P.; Humphreys, I.; Flaxman, A.; Brown, A.; Cooke, G.S.; Pybus, O.G.; Barnes, E. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2015, 61, 77-87.
10. Barrett, S.; Sweeney, M.; Crowe, J. Host immune responses in hepatitis C virus clearance. Eur. J. Gastroenterol. Hepatol. 2005, 17, 1089-1097.
11. Koziel, M.J. Cellular immune responses against hepatitis C virus. Clin. Infect. Dis.2005, 41, S25-S31.
12. Larrubia, J.R.; Moreno-Cubero, E.; Lokhande, M.U.; García-Garzón, S.; Lázaro, A.; Miquel, J.; Perna, C.; Sanz-de-Villalobos, E. Adaptive immune response during hepatitis C virus infection. World J. Gastroenterol. 2014, 20, 3418-3430.
13. Elmore, S. Apoptosis: A review of programmed cell death. Toxicol. Pathol. 2007, 35, 495-516.
14. Barber, G.N. Host defense, viruses and apoptosis. Cell Death Differ. 2001, 8, 113-126.
15. Iannello, A.; Debbeche, O.; Martin, E.; Attalah, L.H.; Samarani, S.; Ahmad, A. Viral strategies for evading antiviral cellular immune responses of the host. J. Leukoc. Biol. 2006, 79, 16-35.
16. Oldstone, M.B.A. Viral persistence: Parameters, mechanisms and future predictions. Virology 2006, 344, 111-118.
17. Mundt, B.; Kühnel, F.; Zender, L.; Paul, Y.; Tillmann, H.; Trautwein, C.; Manns, M.P.; Kubicka, S. Involvement of TRAIL and its receptors in viral hepatitis. FASEB J.2003, 17, 94-96.
18. Silberstein, E.; Ulitzky, L.; Lima, L.A.; Cehan, N.; Teixeira-Carvalho, A.; Roingeard, P.; Taylor, D.R. HCV-mediated apoptosis of hepatocytes in culture and viral pathogenesis. PLoS ONE 2016, 11, e0155708.
19. Park, M.S.; Kim, S.; Patel, J.; Hajdu, C.H.; Do, R.K.; Mannelli, L.; Babb, J.S.; Taouli, B. Hepatocellular carcinoma: Detection with diffusion-weighted versus contrast-enhanced magnetic resonance imaging in pretransplant patients. Hepatology 2012,56, 140-148.
20. Hoshida, Y.; Fuchs, B.C.; Bardeesy, N.; Baumert, T.F.; Chung, R.T. Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma. J. Hepatol.2014, 61, S79-S90.
21. + T cells is enhanced by co-culture with hepatocytes expressing hepatitis C virus (HCV) structural proteins through FasL induction. Virology 2006,346, 363-372.
22. Toubi, E.; Kessel, A.; Goldstein, L.; Slobodin, G.; Sabo, E.; Shmuel, Z.; Zuckerman, E. Enhanced peripheral T-cell apoptosis in chronic hepatitis C virus infection: Association with liver disease severity. J. Hepatol. 2001, 35, 774-780.
23. Muriel, P. Role of free radicals in liver diseases. Hepatol. Int. 2009, 3, 526-536.
24. Eguchi, A.; Wree, A.; Feldstein, A.E. Biomarkers of liver cell death. J. Hepatol.2014, 60, 1063-1074.
25. Barathan, M.; Gopal, K.; Mohamed, R.; Ellegård, R.; Saeidi, A.; Vadivelu, J.; Ansari, A.W.; Rothan, H.A.; Ravishankar Ram, M.; Zandi, K. et al. Chronic hepatitis C virus infection triggers spontaneous differential expression of biosignatures associated with T cell exhaustion and apoptosis signaling in peripheral blood mononucleocytes. Apoptosis 2015, 20, 466-480.
26. Derhovanessian, E.; Solana, R.; Larbi, A.; Pawelec, G. Immunity, ageing and cancer. Immun. Ageing 2008, 5, 11.
27. Chou, J.P.; Effros, R.B. T cell replicative senescence in human aging. Curr. Pharm. Des. 2013, 19, 1680-1698.
28. + T cells and their role in health and disease. Immunology 2011, 134, 17-32.
29. Effros, R.B. The silent war of CMV in aging and HIV infection. Mech. Ageing Dev.2016, 158, 46-52.
30. Janković, V.; Messaoudi, I.; Nikolich-Zugich, J. Phenotypic and functional T-cell aging in rhesus macaques (Macacamulatta): Differential behavior of CD4 and CD8 subsets. Blood 2003, 102, 3244-3251.
31. Maue, A.C.; Yager, E.J.; Swain, S.L.; Woodland, D.L.; Blackman, M.A.; Haynes, L. T-cell immunosenescence: Lessons learned from mouse models of aging. Trends Immunol. 2009, 30, 301-305.
32. Fülöp, T.; Larbi, A.; Pawelec, G. Human T cell aging and the impact of persistent viral infections. Front. Immunol. 2013, 4, 271.
33. Borkow, G.; Bentwich, Z. Chronic immune activation associated with chronic helminthic and human immunodeficiency virus infections: Role of hyporesponsiveness and anergy. Clin. Microbiol. Rev. 2004, 17, 1012-1030.
34. + T cells and their association with HIV-1-induced T cell dysfunction. J. Immunol. 2005, 175, 8415-8423.
35. + T cells in HIV infection. J. Immunol. 2009, 183, 1120-1132.
36. + T cells in HIV/TB co-infection. Cell. Immunol.2015, 297, 19-32.
37. + T cells are preserved only in HIV-infected individuals receiving early treatment. J. Infect. Dis.2007, 195, 108-117.
38. + T-cell changes independent of viral load. Blood2004, 104, 942-947.
39. + T cells. PLoS ONE 2013, 8, e64702.
40. - T cells revisited: Solved or still ongoing? J. Immunol. Res. 2015, 2015, 348746.
41. + T lymphocytes and functional immune deficiency. J. Leukoc. Biol. 2010, 87, 107-116.
42. Ripa, M.; Chiappetta, S.; Tambussi, G. Immunosenescence and hurdles in the clinical management of older HIV-patients. Virulence 2017, 8, 508-528.
43. + mucosal-associated invariant T cells in chronic hepatitis C virus-infected patients. Eur. J. Clin. Investig. 2016, 46, 170-180.
44. Luciano, A.A.; Lederman, M.M.; Valentin-Torres, A.; Bazdar, D.A.; Sieg, S.F. Impaired induction of CD27 and CD28 predicts naive CD4 T cell proliferation defects in HIV disease. J. Immunol. 2007, 179, 3543-3549.
45. Golden-Mason, L.; Burton, J.R., Jr.; Castelblanco, N.; Klarquist, J.; Benlloch, S.; Wang, C.; Rosen, H.R. Loss of IL-7 receptor alpha-chain (CD127) expression in acute HCV infection associated with viral persistence. Hepatology 2006, 44, 1098-1109.
46. + T-cell response: The case of, H.C.V. Rev. Med. Virol. 2011, 21, 347-357.
47. + T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation. J. Hepatol. 2014, 61, 1212-1219.
48. + T cell exhaustion. J. Immunol.2009, 182, 6697-6708.
49. + T cell exhaustion during chronic viral infection. Immunity 2007, 27, 670-684.
50. Jelley-Gibbs, D.M.; Dibble, J.P.; Filipson, S.; Haynes, L.; Kemp, R.A.; Swain, S.L. Repeated stimulation of CD4 effector T cells can limit their protective function. J. Exp. Med. 2005, 201, 1101-1112.
51. Pauken, K.E.; Wherry, E.J. Overcoming T cell exhaustion in infection and cancer. Trends Immunol. 2015, 36, 265-276.
52. + T cell responses to chronic viral infections and cancer. Front. Immunol. 2017, 8, 1215.
53. Schietinger, A.; Greenberg, P.D. Tolerance and exhaustion: Defining mechanisms of T cell dysfunction. Trends Immunol. 2014, 35, 51-60.
54. Sumida, Y.; Niki, E.; Naito, Y.; Yoshikawa, T. Involvement of free radicals and oxidative stress in NAFLD/NASH. Free Radic. Res. 2013, 47, 869-880.
55. Urbani, S.; Amadei, B.; Tola, D.; Massari, M.; Schivazappa, S.; Missale, G. Ferrari CPD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion. J. Virol. 2006, 80, 11398-11403.
56. + T cells during acute HCV infection, irrespective of clinical outcome. J. Virol. 2008, 82, 3154-3160.
57. + T cell responses following splenectomy in hepatitis C virus-related liver cirrhosis. Clin. Exp. Immunol. 2011, 165, 243-250.
58. + T cells closely correlated with hepatitis C virus viral load in chronic hepatitis C patients. Menoufia Med. J. 2016, 29, 383-388.
59. + T-cell response in acute hepatitis C. Gastroenterology 1999, 117, 933-941.
60. Semmo, N.; Day, C.L.; Ward, S.M.; Lucas, M.; Harcourt, G.; Loughry, A.; Klenerman, P. Preferential loss of IL-2-secreting CD4+ T helper cells in chronic HCV infection. Hepatology 2005, 41, 1019-1028.
61. + T cells in patients with chronic infection. Gastroenterology 2011, 141, 1422-1431.
62. + T cells of chronic HCV-infected patients express multiple negative immune checkpoints following stimulation with HCV peptides. Cell. Immunol. 2017, 313, 1-9.
63. Rojas, J.M.; Avia, M.; Martín, V.; Sevilla, N. IL-10: A multifunctional cytokine in viral infections. J. Immunol. Res. 2017, 2017, 6104054.
64. Kurioka, A.; Walker, L.J.; Klenerman, P.; Willberg, C.B. MAIT cells: New guardians of the liver. Clin. Transl. Immunol. 2017, 6, e132.
65. Xiao, X.; Cai, J. Mucosal-associated invariant T cells: New insights into antigen recognition and activation. Front. Immunol. 2017, 8, 1540.
66. Cianferoni, A. Invariant natural killer T cells. Antibodies 2014, 3, 16-36.
67. Kjer-Nielsen, L.; Patel, O.; Corbett, A.J.; Le Nours, J.; Meehan, B.; Liu, L.; Bhati, M.; Chen, Z.; Kostenko, L.; Reantragoon, R. et al. MR1 presents microbial vitamin B metabolites to MAIT cells. Nature 2012, 491, 717-723.
68. Wakao, H.; Fujita, H. Toward the realization of cell therapy: The advent of MAIT cells from iPSCs. Cell Cycle 2013, 12, 2341-2342.
69. Le Bourhis, L.; Martin, E.; Péguillet, I.; Guihot, A.; Froux, N.; Coré, M.; Lévy, E.; Dusseaux, M.; Meyssonnier, V.; Premel, V. et al. Antimicrobial activity of mucosal-associated invariant T cells. Nat. Immunol. 2010, 11, 701-708.
70. Gold, M.C.; Lewinsohn, D.M. Mucosal associated invariant T cells and the immune response to infection. Microbes Infect. 2011, 13, 742-748.
71. Ussher, J.E.; Klenerman, P.; Willberg, C.B. Mucosal-associated invariant T-cells: New players in anti-bacterial immunity. Front. Immunol. 2014, 5, 450.
72. Saeidi, A.; Ellegård, R.; Yong, Y.K.; Tan, H.Y.; Velu, V.; Ussher, J.E.; Larsson, M.; Shankar, E.M. Functional role of mucosal-associated invariant T cells in HIV infection. J. Leukoc. Biol. 2016, 100, 305-314.
73. Le Bourhis, L.; Guerri, L.; Dusseaux, M.; Martin, E.; Soudais, C.; Lantz, O. Mucosal-associated invariant T cells: Unconventional development and function. Trends Immunol. 2011, 32, 212-218.
74. Simoni, Y.; Diana, J.; Ghazarian, L.; Beaudoin, L.; Lehuen, A. Therapeutic manipulation of natural killer (NK) T cells in autoimmunity: Are we close to reality? Clin. Exp. Immunol. 2013, 171, 8-19.
75. van Wilgenburg, B.; Scherwitzl, I.; Hutchinson, E.C.; Leng, T.; Kurioka, A.; Kulicke, C.; de Lara, C.; Cole, S.; Vasanawathana, S.; Limpitikul, W. et al. MAIT cells are activated during human viral infections. Nat. Commun. 2016, 7, 11653.
76. Hengst, J.; Strunz, B.; Deterding, K.; Ljunggren, H.G.; Leeansyah, E.; Manns, M.P.; Cornberg, M.; Sandberg, J.K.; Wedemeyer, H.; Björkström, N.K. Nonreversible MAIT cell-dysfunction in chronic hepatitis C virus infection despite successful interferon-free therapy. Eur. J. Immunol. 2016, 46, 2204-2210.
77. Spaan, M.; Hullegie, S.J.; Beudeker, B.J.; Kreefft, K.; van Oord, G.W.; Groothuismink, Z.M.; van Tilborg, M.; Rijnders, B.; de Knegt, R.J.; Claassen, M.A. et al. Frequencies of circulating MAIT cells are diminished in chronic HCV, HIV and HCV/HIV co-infection and do not recover during therapy. PLoS ONE 2016, 11, e0159243.
78. Bolte, F.J.; O’Keefe, A.C.; Webb, L.M.; Serti, E.; Rivera, E.; Liang, T.J.; Ghany, M.; Rehermann, B. Intra-hepatic depletion of mucosal-associated invariant T cells in hepatitis C virus-induced liver inflammation. Gastroenterology 2017, 153, 1392-1403.
79. Shrivastava, S.; Steele, R.; Ray, R.; Ray, R.B. MicroRNAs: Role in hepatitis C virus pathogenesis. Genes Dis. 2015, 2, 35-45.
80. Bandiera, S.; Pernot, S.; El Saghire, H.; Durand, S.C.; Thumann, C.; Crouchet, E.; Ye, T.; Fofana, I.; Oudot, M.A.; Barths, J. et al. HCV-induced up-regulation of miR-146a-5p in hepatocytes promotes viral infection and deregulates metabolic pathways associated with liver disease pathogenesis. J. Virol. 2016, 90, 6387-6400.
81. Bandiera, S.; Pfeffer, S.; Baumert, T.F.; Zeisel, M.B. miR-122-A key factor and therapeutic target in liver disease. J. Hepatol. 2015, 62, 448-457.